Source: FinanzNachrichten

Renova Therapeutics: Renova Therapeutics Announces Strategic Focus and Roadmap Prioritization for Its Gene Therapies to Treat Heart Failure and Type 2 Diabetes Mellitus

Renova Has Prioritized Two Primary Regulatory Pathways Where It Is Poised to Launch Pivotal Human Trials for Its Promising Gene Therapies to Treat Heart Failure and Type 2 Diabetes MellitusCARLSBAD...

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Vijay Mahant's photo - CEO of Renova Therapeutics

CEO

Vijay Mahant

CEO Approval Rating

82/100

Read more